金龍蛇顆粒對(duì)缺氧環(huán)境下胃癌BGC-823細(xì)胞上皮間質(zhì)轉(zhuǎn)化的影響
徐晶鈺,張璇,裴蓓,秦志豐,陸燁,魏品康*
(解放軍第二軍醫(yī)大學(xué)長(zhǎng)征醫(yī)院中醫(yī)科,上海 200003)
摘要:目的探討金龍蛇顆粒對(duì)缺氧狀態(tài)下胃癌BGC-823細(xì)胞上皮間質(zhì)轉(zhuǎn)化(EMT)的影響并初步研究該過(guò)程的相關(guān)機(jī)理。方法將胃癌BGC-823細(xì)胞分成3組:常氧對(duì)照組、缺氧對(duì)照組(加入150 μmol/L的CoCl2)、金龍蛇顆粒含藥血清組。觀察3組細(xì)胞形態(tài)變化;RT-PCR檢測(cè)3組細(xì)胞E-cad、N-cad、Vimentin mRNA表達(dá)變化。結(jié)果常氧對(duì)照組的胃癌BGC-823細(xì)胞排列較致密,為上皮樣表現(xiàn);缺氧對(duì)照組大部分細(xì)胞排列較前松散,形態(tài)較前拉長(zhǎng),呈間質(zhì)樣表現(xiàn);金龍蛇顆粒含藥血清組介于二者之間。金龍蛇顆粒含藥血清組與缺氧對(duì)照組相比,E-cad mRNA表達(dá)升高,N-cad、Vimentin mRNA表達(dá)降低,差異有顯著統(tǒng)計(jì)學(xué)意義(P<0.01)。結(jié)論金龍蛇顆??梢种迫毖醐h(huán)境中胃癌BGC-823細(xì)胞的上皮間質(zhì)轉(zhuǎn)化,可能與其下調(diào)N-cad、Vimentin mRNA表達(dá),升高E-cad mRNA表達(dá)相關(guān)。
關(guān)鍵詞:金龍蛇顆粒;E-cad;N-cad;Vimentin;上皮間質(zhì)轉(zhuǎn)化;缺氧;大鼠
DOI:10.13463/j.cnki.jlzyy.2015.08.023
中圖分類號(hào):R273文獻(xiàn)標(biāo)志碼: A
文章編號(hào):1003-5699(2015)08-0830-03
基金項(xiàng)目:國(guó)家自然科學(xué)基金(81302933,81202678);上海市中醫(yī)藥事業(yè)發(fā)展3年行動(dòng)計(jì)劃(ZYSNXD-CC-ZDYJ024);第二軍醫(yī)大學(xué)青年啟動(dòng)基金(2012QN17)資助。
作者簡(jiǎn)介:徐晶鈺(1983-),男,碩士,主治醫(yī)師,主要從事中西醫(yī)結(jié)合腫瘤防治。
收稿日期:(責(zé)任編輯:趙玉芝2014-12-21)
*通信作者:魏品康,電話-(021)81885474,電子信箱-zhangxuan0918@163.com
Jinlongshe Granules on epithelial-mesenchymal transition in gastric
cancer cells BGC-823 under hypoxia microenvironment
XU Jingyu,ZHANG Xuan,PEI Bei,QIN Zhifeng,LU Ye,WEI Pinkang*
(Department of Traditional Chinese Medicine,Changzheng Hospital Affiliated to Second Military
Medical University,Shanghai 200003,China)
Abstract:ObjectiveTo investigate the effects of Jinlongshe granules on EMT of gastric cancer cell BGC-823 under the microenvironment of hypoxia,and to explore the mechanism of the process.MethodsThe cells were divided into three groups:normal control group(cultured under normal condition);hypoxia control group(cultured with CoCl2);Jinlongshe granules group(co-cultured with CoCl2 and Chinese herbal medicine serum).Microscopy was used to observe the different morphological change among the three groups and E-cad,N-cad,Vimentin mRNA were detected by RT-PCR.ResultsThe cells of normal control group became close together like epithelial features;the cells of hypoxia control group became loose like mesenchymal features;the result of Jinlongshe granules group was between the other two groups.RT-PCR showed that the E-cad mRNA of Jinlongshe granules group was raised significant and the N-cad,Vimentin mRNA of Jinlongshe granules group was reduced significant compared with hypoxia control group (P<0.01).ConclusionJinlongshe granules can inhibit the EMT of gastric cancer cell BGC-823 under the microenvironment of hypoxia.The mechanism maybe related to the reduction of N-cad,Vimentin mRNA and raise of E-cad mRNA.
Keywords:Jinlongshe granules;E-cad;N-cad;Vimentin;epithelial-mesenchymal transition;hypoxia;rat
胃癌是國(guó)內(nèi)常見的惡性腫瘤,發(fā)病率高居第二位[1]。由于發(fā)病時(shí)多處于中晚期,其主要治療方式為手術(shù)和化療,療效始終不能令人滿意[2]。原發(fā)灶的侵襲轉(zhuǎn)移是致死和導(dǎo)致生活質(zhì)量下降的重要原因[3]。中醫(yī)藥在胃癌輔助治療上具有明顯的優(yōu)勢(shì),可以對(duì)患者整體調(diào)節(jié),改善體內(nèi)環(huán)境,毒副作用小,因此研究有效的復(fù)方制劑勢(shì)在必行[4]。金龍蛇制劑是我科治療胃癌的經(jīng)驗(yàn)方,以消痰散結(jié)為治則,由魏品康教授經(jīng)40余年臨床經(jīng)驗(yàn)總結(jié)而成,療效確切[5]。本研究將從缺氧環(huán)境中胃癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化角度,進(jìn)一步對(duì)金龍蛇顆粒逆轉(zhuǎn)胃癌細(xì)胞侵襲轉(zhuǎn)移的作用機(jī)制進(jìn)行探討。
1實(shí)驗(yàn)材料
制南星、制半夏、山慈菇等中藥材均購(gòu)自上海雷允上中藥飲片藥材有限公司,符合2010年版《中華人民共和國(guó)藥典》檢測(cè)標(biāo)準(zhǔn),由第二軍醫(yī)大學(xué)附屬上海長(zhǎng)征醫(yī)院制劑室制成含生藥材53.3 g/mL的浸膏;CoCl2來(lái)自Sigma公司;E-cad抗體、N-cad抗體、Vimentin抗體均來(lái)自Abcam公司。二氧化碳培養(yǎng)箱來(lái)自SANYO;倒置顯微鏡來(lái)自重慶光電有限公司;酶標(biāo)儀來(lái)自普朗DNM-9602。清潔級(jí)雄性SD大鼠,280~320 g,由中科院上海試驗(yàn)動(dòng)物中心提供,許可證號(hào):SCXK(滬):2012-0002;胃癌BGC-823細(xì)胞,由中科院上海細(xì)胞庫(kù)提供。
2實(shí)驗(yàn)方法
2.1金龍蛇顆粒含藥血清的制備大鼠隨機(jī)分為金龍蛇顆粒組和空白對(duì)照組,各5只。金龍蛇顆粒組予中藥浸膏21.36 g/kg灌胃,每天早8點(diǎn),午1點(diǎn);空白對(duì)照組每次給予生理鹽水2 mL。連續(xù)給藥5 d,末次給藥后1 h,麻醉大鼠,摘眼球取血,采血前禁食不禁水12 h,室溫下靜置1 h,5 000 r/min,10 min離心,56 ℃水浴滅活30 min,過(guò)濾分裝采用0.22 μm濾膜,存放于-20 ℃。
2.2細(xì)胞分組胃癌細(xì)胞復(fù)蘇,密度調(diào)至1×106個(gè)/mL后均勻接種于96孔培養(yǎng)板中,培養(yǎng)于37 ℃、5%CO2、含10%胎牛血清的RPMI-1640培養(yǎng)液中。常氧對(duì)照組:繼續(xù)培養(yǎng)24 h;缺氧模型組:用150 μmol/L CoCl2加入培養(yǎng)基中,再繼續(xù)培養(yǎng)24 h;金龍蛇顆粒含藥血清組:先加入含藥血清,再用150 μmol/L CoCl2處理胃癌細(xì)胞,置于培養(yǎng)箱內(nèi)培養(yǎng)。
2.3觀察胃癌BGC-823細(xì)胞形態(tài)變化按上述分組,倒置顯微鏡觀察細(xì)胞形態(tài)變化。RT-PCR檢測(cè)各組細(xì)胞E-Cad、N-cad、Vimentin mRNA表達(dá),按RT-PCR試劑盒說(shuō)明書進(jìn)行操作。根據(jù)說(shuō)明書提取RNA,實(shí)時(shí)定量PCR檢測(cè)各目標(biāo)基因mRNA。內(nèi)參選用GAPDH,由上海Invitrogen公司設(shè)計(jì)合成引物。引物序列見表1。
表1 各基因PCR引物序列
3實(shí)驗(yàn)結(jié)果
3.1倒置顯微鏡觀察胃癌BGC-823細(xì)胞形態(tài)變化常氧對(duì)照組細(xì)胞排列較致密,大部分為上皮細(xì)胞表現(xiàn),缺氧對(duì)照組大部分細(xì)胞排列較前松散,形態(tài)有所改變,較前拉長(zhǎng),呈間質(zhì)樣表現(xiàn)。金龍蛇顆粒含藥血清組介于二者之間。
3.2RT-PCR檢測(cè)金龍蛇顆粒對(duì)胃癌BGC-823細(xì)胞E-Cad、N-cad、Vimentin mRNA表達(dá)的影響見表2。
組 別E-CadN-cadVimentin常氧對(duì)照組 1.00±0.00 1.00±0.00 1.00±0.00 缺氧對(duì)照組 0.32±0.03#1.65±0.07#1.80±0.08#金龍蛇顆粒血清組0.63±0.05△1.33±0.07△1.39±0.07△
注:與常氧對(duì)照組比較,#P<0.01;與缺氧對(duì)照組比較,△P<0.01
缺氧對(duì)照組與常氧對(duì)照組E-cad mRNA表達(dá)比較明顯降低,N-cad、Vimentin mRNA表達(dá)比較明顯升高,差異有統(tǒng)計(jì)學(xué)意義;金龍蛇顆粒含藥血清組與缺氧對(duì)照組相比,E-cad mRNA表達(dá)升高,N-cad、Vimentin mRNA表達(dá)降低,差異有統(tǒng)計(jì)學(xué)意義。
4討論
由于腫瘤惡性增殖,新生血管生成相對(duì)不足,使整個(gè)腫瘤處于缺氧環(huán)境中[6]。缺氧容易導(dǎo)致腫瘤細(xì)胞發(fā)生上皮間質(zhì)轉(zhuǎn)化[7],而上皮間質(zhì)轉(zhuǎn)化又是腫瘤細(xì)胞侵襲轉(zhuǎn)移的重要前提[8]。因此從上皮間質(zhì)轉(zhuǎn)化入手,探討抑制胃癌侵襲轉(zhuǎn)移具有十分明確的現(xiàn)實(shí)意義。
細(xì)胞發(fā)生上皮間質(zhì)轉(zhuǎn)化需要特征[9]:1)細(xì)胞形態(tài)的改變。由緊密排列的立方上皮樣細(xì)胞向松散的紡錘間質(zhì)細(xì)胞轉(zhuǎn)變;2)上皮標(biāo)記物向間質(zhì)標(biāo)記物的轉(zhuǎn)變。E-cad表達(dá)的喪失標(biāo)志著細(xì)胞發(fā)生EMT[10];而間質(zhì)特性的標(biāo)記物N-cad、Vimentin表達(dá)的增高意味著細(xì)胞運(yùn)動(dòng)能力提高,則更容易發(fā)生侵襲轉(zhuǎn)移[11]。
我科前期已經(jīng)就“從痰論治胃癌”做了大量研究。魏品康教授在經(jīng)典痰證理論上進(jìn)行創(chuàng)新,提出腫瘤“痰污染”學(xué)說(shuō),并認(rèn)為腫瘤缺氧微環(huán)境也屬于“痰污染”[12],以消痰散結(jié)為治則的金龍蛇顆??梢郧宄滴廴?,對(duì)胃癌療效確切[13]。實(shí)驗(yàn)上可以干擾胃癌細(xì)胞增殖[14];促進(jìn)胃癌細(xì)胞凋亡[15];抑制胃癌侵襲轉(zhuǎn)移[16];影響胃癌新生血管生成[17]等;臨床上可以延長(zhǎng)患者生存期,提高患者生活質(zhì)量[18]等。
相對(duì)于缺氧對(duì)照組,金龍蛇顆粒不僅能使胃癌細(xì)胞形態(tài)變化發(fā)生部分逆轉(zhuǎn),細(xì)胞間的聯(lián)接由松散變得致密;同時(shí)也使上皮間質(zhì)轉(zhuǎn)化過(guò)程中的上皮樣標(biāo)記物(E-cad)有所提高,間質(zhì)樣標(biāo)記物(N-cad、Vimentin)有所降低,證實(shí)了金龍蛇顆粒能逆轉(zhuǎn)缺氧環(huán)境中胃癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化。
在今后的研究中,我們將進(jìn)一步探討金龍蛇顆粒逆轉(zhuǎn)缺氧環(huán)境中胃癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化的機(jī)理,這將對(duì)從痰論治胃癌侵襲轉(zhuǎn)移提供新的實(shí)驗(yàn)依據(jù)。
參考文獻(xiàn):
[1]孫秀娣,牧人,周有尚,等.中國(guó)胃癌死亡率20年變化情況分析及其發(fā)展趨勢(shì)預(yù)測(cè)[J].中華腫瘤雜志,2004,26(1):4-9.
[2]孫婷,李平,張梅.晚期胃癌維持治療現(xiàn)狀[J].吉林中醫(yī)藥,2014,34(10):1077-1080.
[3]HARTGRINK H H,JANSEN E P.Nicole CT van Grieken.Gastric Cancer[J].The Lancet,2009,374(9688):477-490.
[4]張慈安,魏品康,秦志豐.胃癌的中醫(yī)研究進(jìn)展[J].長(zhǎng)春中醫(yī)藥大學(xué)學(xué)報(bào),2007,23(2):80-82.
[5]武峰,秦志豐,張慈安,等.金龍蛇顆粒對(duì)胃癌術(shù)后患者生存質(zhì)量的影響[J].中國(guó)中西醫(yī)結(jié)合消化雜志,2012,20(7):289-292.
[6]TSAI Y P,WU K J.Hypoxia-regulated target genes implicated in tumor metastasis[J].Journal of Biomedical Science,2012,19(1):102.
[7]MOHLA S.Tumor microenvironment[J].Journal of Cellular Biochemistry,2007,101(4):801-804.
[8]LEE J M,DEDHAR S,KALLURI R,et al.The epithelial-mesenchymal transition:new insights in signaling,development,and disease[J].Journal of Cell Biology,2006,172(7):973-981.
[9]SHIRAHATA A,SAKURABA K,KITAMURA Y,et al.Detection of vimentin methylation in the serum of patients with gastric Cancer[J].Anticancer Research,2012,32(3):791-794.
[10]COWIN P,ROWLANDS T M,HATSELL S J.Cadherins and catenins in breast Cancer[J].Current Opinion in Cell Biology,2005(17):499-508.
[11]CHALASANI K,BREWSTER R M.N-cadherin-mediated cell adhesion restricts cell proliferation in the dorsal neural tube[J].Molecular Biology of the Cell,2011,22(9):1505-1515.
[12]劉煊,修麗娟,陸燁,等.以取象比類法研究胃癌痰本質(zhì)[J].中醫(yī)雜志,2015,56(7):623-625.
[13]徐晶鈺,張璇,裴蓓,等.從痰論治胃癌缺氧微環(huán)境逆轉(zhuǎn)細(xì)胞上皮間質(zhì)轉(zhuǎn)化理論探析[J].吉林中醫(yī)藥,2014,34(5):433-436.
[14]孫大志,葉敏,矯健鵬,等.消痰散結(jié)方及其拆方對(duì)S180腫瘤生長(zhǎng)與腫瘤相關(guān)基因蛋白表達(dá)影響的研究[J].中國(guó)藥物與臨床,2011,11(3):248-251,后插1-后插2.
[15]桂牧微,魏品康,陸燁,等.消痰散結(jié)方藥物血清對(duì)人胃癌MKN-45細(xì)胞增殖和凋亡的影響[J].中西醫(yī)結(jié)合學(xué)報(bào),2010,8(3):250-255.
[16]許玲,魏品康,陳亞琳,等.中藥消痰散結(jié)方抑制裸鼠原位移植人胃癌SGC-7901的生長(zhǎng)轉(zhuǎn)移[J].世界華人消化雜志,2004,12(5):1015-1020.
[17]龐斌,魏品康,李勇進(jìn),等.消痰散結(jié)方對(duì)裸鼠MKN-45人胃癌組織中VEGF-C及其受體VEGFR-3表達(dá)的影響[J].中國(guó)中西醫(yī)結(jié)合雜志,2011,31(2):204-208.
[18]施俊,秦志豐,王曉偉,等.消痰散結(jié)中醫(yī)治療方案用于胃癌術(shù)后臨床觀察[J].中國(guó)中醫(yī)藥信息雜志,2011,18(10):14-17.